958 results on '"Merkelbach-Bruse, Sabine"'
Search Results
2. Endometriumkarzinom: molekulare Klassifikation in der Routinepathologie
3. High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methods
4. Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score
5. Multinational proficiency tests for EGFR exon 20 insertions reveal that the assay design matters
6. TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases
7. Benchmarking whole exome sequencing in the German network for personalized medicine
8. Testing for deficient mismatch repair and microsatellite instability: A focused update
9. Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer
10. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
11. Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität: Eine fokussierte Aktualisierung
12. TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading
13. Genomic ALK alterations in primary and relapsed neuroblastoma
14. Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
15. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer
16. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC
17. Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
18. Erratum zu: Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität
19. ROS1: Rearrangements und Analytik
20. Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors
21. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer
22. Multicenter Evaluation of the Idylla GeneFusion in Non–Small-Cell Lung Cancer
23. Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
24. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC
25. Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report
26. MSI testing: What’s new? What should be considered?
27. Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy
28. Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
29. MSI-Testung: Was ist neu? Was ist zu beachten?
30. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence
31. Multi-center real-world comparison of the fully automated Idylla™ microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer
32. Genomic Applications in Pulmonary Malignancies
33. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
34. Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes
35. Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations
36. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung
37. Reply to Fumihiko Urabe, Takashi Yoshioka, and Takahiro Kimura’s Letter to the Editor re: Felix Seelemeyer, David Pfister, Robert Pappesch, Sabine Merkelbach-Bruse, Pia Paffenholz and Axel Heidenreich. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021
38. Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen
39. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
40. Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
41. Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
42. Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation
43. Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158]
44. Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors
45. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
46. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies
47. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
48. Implementing TMB measurement in clinical practice: considerations on assay requirements
49. Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors
50. Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.